First Dallas Securities Inc. Sells 2,700 Shares of Pfizer Inc. (NYSE:PFE)

First Dallas Securities Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.7% in the 3rd quarter, Holdings Channel reports. The firm owned 22,600 shares of the biopharmaceutical company’s stock after selling 2,700 shares during the quarter. First Dallas Securities Inc.’s holdings in Pfizer were worth $654,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Gladius Capital Management LP raised its holdings in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer in the second quarter valued at about $29,000. Quarry LP bought a new stake in shares of Pfizer in the second quarter valued at about $31,000. Financial Connections Group Inc. bought a new stake in shares of Pfizer in the second quarter valued at about $34,000. Finally, Teachers Insurance & Annuity Association of America purchased a new position in Pfizer in the third quarter valued at about $35,000. 68.36% of the stock is currently owned by institutional investors.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 1.5 %

Shares of PFE stock opened at $26.12 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $148.02 billion, a price-to-earnings ratio of 35.30, a PEG ratio of 0.70 and a beta of 0.65. The stock has a 50 day simple moving average of $27.42 and a 200-day simple moving average of $28.36. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.17) EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 8th were issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.43%. The ex-dividend date of this dividend was Friday, November 8th. Pfizer’s payout ratio is currently 227.03%.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.